Medincell SA
PAR:MEDCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medincell SA
Free Cash Flow
Medincell SA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Medincell SA
PAR:MEDCL
|
Free Cash Flow
-€18.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Sanofi SA
PAR:SAN
|
Free Cash Flow
€10.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Free Cash Flow
€827.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
19%
|
|
|
Vetoquinol SA
PAR:VETO
|
Free Cash Flow
€49.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
Virbac SA
PAR:VIRP
|
Free Cash Flow
€96.9m
|
CAGR 3-Years
29%
|
CAGR 5-Years
1%
|
CAGR 10-Years
36%
|
|
|
Boiron SA
PAR:BOI
|
Free Cash Flow
€37.3m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
Medincell SA
Glance View
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. The company is headquartered in Jacou, Occitanie and currently employs 150 full-time employees. The company went IPO on 2018-10-08. The firm is focused on the development of therapeutic solutions with worldwide access. The firm works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
See Also
What is Medincell SA's Free Cash Flow?
Free Cash Flow
-18.9m
EUR
Based on the financial report for Sep 30, 2025, Medincell SA's Free Cash Flow amounts to -18.9m EUR.
What is Medincell SA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-12%
The average annual Free Cash Flow growth rates for Medincell SA have been 5% over the past three years , -12% over the past five years .